No profile data available.
Marizyme, Inc. (MRZM) is a healthcare company in the heart treatment equipment industry, based in Jupiter, United States.
It reported revenue of $645,810 for fiscal year 2023, up 176.6% from fiscal year 2022, and net income of -$69.54 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $0, down 100.0% from a year before. Its market capitalization was $39,537 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
, a multi-technology life science company, engages in the research, manufacture, and commercialization of medical devices, diagnostics, and products to address clinical needs in the United States, Europe, and Asia. The company operates as a medical technology company that delivers solutions for coronary artery bypass graft surgery.
Marizyme reported $645,810 in revenue for fiscal year 2023, up 176.6% from $233,485 in fiscal year 2022. In Q3 2024 revenue was $0.
$39,537 as of October 8, 2026.
Listed companies of a similar size in the same industry (heart treatment equipment) include Nuwellis, Inc. (NUWE), Biotricity, Inc. (BTCY), Catheter Precision, Inc. (VTAK).